Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Estrogen receptor (ER) expression in breast cancer plays an essential role in carcinogenesis and disease progression. Recently, tumors with low level (1%-10%) of ER expression have been separately defined as ER low positive (ERlow). It is suggested that ERlow tumors might be morphologically and behaviorally different from tumors with high ER expression (ERhigh). Materials and methods: Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for early breast cancer and had available medical records were included for analysis. Difference in clinicopathological characteristics, endocrine responsiveness and five-year recurrence-free survival was evaluated between different ER subgroups (ERhigh, ERlow, and ER-negative [ER-]). Results: A total of 2,162 breast cancer patients were included in the analysis, Tis and T1 stage. Among them, 1,654 (76.5%) were ERhigh, 54 (2.5%) were ERlow, and 454 (21.0%) were ER- patients. ERlow cases were associated with smaller size, higher histologic grade, positive human epidermal growth factor receptor 2, negative progesterone receptor, and higher Ki-67 expression. Recurrence rate was highest in ER- tumors and was inversely proportional to ER expression. Recurrence-free survival was not affected by hormonal therapy in the ERlow group (p=0.418). Conclusion: ERlow breast cancer showed distinct clinicopathological features. ERlow tumors seemed to have higher recurrence rates compared to ERhigh tumors, and they showed no significant benefit from hormonal therapy. Future large scale prospective studies are necessary to validate the treatment options for ERlow breast cancer.
Abstract
Purpose: Estrogen receptor (ER) expression in breast cancer plays an essential role in carcinogenesis and disease progression. Recently, tumors with low level (1%-10%) of ER expression have been separately defined as ER low positive (ERlow). It is suggested that ERlow tumors might be morphologically and behaviorally different from tumors with high ER expression (ERhigh). Materials and methods: Retrospective analysis of a prospective cohort database was performed. Patients who underwent curative surgery for early breast cancer and had available medical records were included for analysis. Difference in clinicopathological characteristics, endocrine responsiveness and five-year recurrence-free survival was evaluated between different ER subgroups (ERhigh, ERlow, and ER-negative [ER-]). Results: A total of 2,162 breast cancer patients were included in the analysis, Tis and T1 stage. Among them, 1,654 (76.5%) were ERhigh, 54 (2.5%) were ERlow, and 454 (21.0%) were ER- patients. ERlow cases were associated with smaller size, higher histologic grade, positive human epidermal growth factor receptor 2, negative progesterone receptor, and higher Ki-67 expression. Recurrence rate was highest in ER- tumors and was inversely proportional to ER expression. Recurrence-free survival was not affected by hormonal therapy in the ERlow group (p=0.418). Conclusion: ERlow breast cancer showed distinct clinicopathological features. ERlow tumors seemed to have higher recurrence rates compared to ERhigh tumors, and they showed no significant benefit from hormonal therapy. Future large scale prospective studies are necessary to validate the treatment options for ERlow breast cancer.
참고문헌 (24)
- Polyak K, "Heterogeneity in breast cancer", J Clin Invest, 121, pp.3786~3788 (2011)
- Sestak I, "Risk stratification in early breast cancer in premenopausal and postmenopausal women : integrating genomic assays with clinicopathological features", Curr Opin Oncol, 31, pp.29~34 (2019)
- Yip CH, "Estrogen and progesterone receptors in breast cancer", Future Oncol, 10, pp.2293~2301 (2014)
- Balleine RL, "High-risk estrogen-receptor-positive breast cancer : identification and implications for therapy", Mol Diagn Ther, 16, pp.235~240 (2012)
- Anderson WF, "Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database", Breast Cancer Res Treat, 76, pp.27~36 (2002)
- Althuis MD, "Etiology of hormone receptor-defined breast cancer : a systematic review of the literature", Cancer Epidemiol Biomarkers Prev, 13, pp.1558~1568 (2004)
- Early Breast Cancer Trialists’ Collaborative Group, "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- Davies E, "New therapeutic approaches in breast cancer", Maturitas, 68, pp.121~128 (2011)
- Allison KH, "Estrogen and progesterone receptor testing in breast cancer : ASCO", CAP Guideline Update, 2020, pp.38, 1346~1366
- Honma N, "Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy", Breast, 23, pp.754~762 (2014)
- Balduzzi A, "Survival outcomes in breast cancer patients with low estrogen", progesterone receptor expression, 2014, pp.14, 258~264
- Gloyeske NC, "Low ER+ breast cancer : is this a distinct group?", Am J Clin Pathol, 141, pp.697~701 (2014)
- Heldring N, "Estrogen receptors : how do they signal and what are their targets", Physiol Rev, 87, pp.905~931 (2007)
- Van den Eynden GG, "Comparative analysis of the biochemical and immunohistochemical determination of hormone receptors in invasive breast carcinoma influence of the tumor-stroma ratio", Pathol Res Pract, 198, pp.517~524 (2002)
- Sparano JA, "Development of the 21-gene assay and its application in clinical practice and clinical trials", J Clin Oncol, 26, pp.721~728 (2008)
- Andre F, "Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer : results from a pooled analysis", J Clin Oncol, 26, pp.2636~2643 (2008)
- Chen T, "Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy : a systematic review and meta-analysis", Clin Breast Cancer, 18, pp.1~8 (2018)
- Hammond ME, "American Society of Clinical Oncology", College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, 2010, pp.28, 2784~2795
- Yi M, "Which threshold for ER positivity? a retrospective study based on 9639 patients", Ann Oncol, 25, pp.1004~1011 (2014)
- Poon IK, "The significance of highlighting the oestrogen receptor low category in breast cancer", Br J Cancer, 123, pp.1223~1227 (2020)
- Viale G, "Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer : BIG 1-98", J Clin Oncol, 25, pp.3846~3852 (2007)
- Ogawa Y, "Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer : analysis for a cut-offpoint as the predictor for endocrine therapy", Breast Cancer, 11, pp.267~275 (2004)
- Collins LC, "Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer : an analysis of 825 cases", Am J Clin Pathol, 123, pp.16~20 (2005)
- Fujii T, "Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer", Ann Oncol, 28, pp.2420~2428 (2017)